Private medical device and artificial intelligence (AI)-led company, BrightHeart, has revealed two studies which show an improvement to pre-natal care through the use of AI technology which received clearance from the US Food and Drug Administration (FDA) in November 2024.

At the Society for Maternal-Fetal Medicines 2025 Meeting in Colorado, US, two groundbreaking studies were presented that could revolutionise prenatal care. The first study, which investigated detection rates in prenatal ultrasounds suspicious for congenital heart defects (CHDs), highlighted that, through the use of the AI software, a 15.3% increase in sensitivity was noted. Additionally, there was an 18% reduction in reading time, improving efficiency among obstetrician and gynocologists (OB-GYNs) and maternal-foetal medicine (MFM) specialists.

Cécile Dupont, CEO of BrightHeart and partner at Sofinnova Partners, stated: “The results presented at SMFM 2025 underscore BrightHeart’s unwavering commitment to innovation in maternal-foetal care. This technology has the power to transform clinical practice, making expert-level diagnostics accessible to all, regardless of location or specialist availability.”

The second study, which focused on how AI can accurately detect foetal ultrasound findings suspicious for major congenital heart defects, revealed that it could identify exams associated with severe CHDs with a sensitivity of 98.7%. Similarly, the software could confirm the absence of signs associated with severe CHD with a specificity of 97.7%. This data has the potential to be further utilised in the field of prenatal care to alter the rate at which CHDs are detected.